Publicaciones
El conocimiento generado en IrsiCaixa se comparte con la comunidad científica a través de la publicación de artículos en revistas científicas de alto impacto.
Post-vaccination IgG4 and IgG2 class switch associates with increased risk of SARS-CoV-2 infections.
SARS-Cov-2 vaccination strategies in hospitalized recovered COVID-19 patients: a randomized clinical trial (VATICO Trial).
Doravirine/islatravir (100/0.75 mg) once-daily compared to bictegravir/emtricitabine/tenofovir alafenamide as initial HIV-1 treatment: 48-week results from a phase 3, randomized, controlled, double-blind, non-inferiority trial.
Therapeutic response to an empirical praziquantel treatment in long-staying sub-Saharan African migrants with positive Schistosoma serology and chronic symptoms: a prospective cohort study in Spain.
Plasma exchange therapy for the post COVID-19 condition: a phase II, double-blind, placebo-controlled, randomized trial.
Non-canonical HIV drug resistance mutations: need to close existing gaps.
Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial.
Safety, immunogenicity and effect on viral rebound of HTI vaccines combined with a TLR7 agonist in early-treated HIV-1 infection: a randomized, placebo-controlled phase 2a trial.
Multikinase Treatment of Glioblastoma: Evaluating the Rationale for Regorafenib.
NK cell depletion in bispecific antibody therapy is associated with lack of HIV control after ART interruption.